Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s TV Ad Review Is Unconstitutional, PhRMA Says, Or Maybe Should Be A Reg

Executive Summary

A draft guidance that outlines six categories of drug ads FDA wants submitted for prior review is a violation of advertisers’ free speech rights, the industry group argues. Other comments float a storyboard compromise.

You may also be interested in...



Drug Sample Reporting Must Be Streamlined, PhRMA Tells FDA

FDA could be flooded with “millions of duplicative signatures” every time a health care practitioner requests a drug sample, the trade group warns.

Biosimilars’ Next Big Hurdle For FDA Could Be Clinician Education

Companies and other groups want clear FDA communication on biosimilars as pharmacists look for an Orange Book-like reference manual to be ready for prescriptions.

DTC Pre-review Requirement Broadly Defined Under FDA Draft Guidance

The agency’s draft guidance on prereview of television advertisements also requires companies to submit the information they rely on to support claims in an ad.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054472

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel